Nathan J. Dowden
CIK: 0001873392
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Entrada Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (19 total)
- Sep 2, 2026TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct2.5K shares at avg. $7.14$18K - May 4, 2026TRDA
Entrada Therapeutics, Inc.
Exercise(M)Direct15K shares at avg. $1.74$26K - May 4, 2026TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct15K shares at avg. $15.33$230K - Mar 10, 2026TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct11.9K shares at avg. $13.05$155K - Mar 9, 2026TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct3.1K shares at avg. $13.02$41K - Mar 3, 2026TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct14K shares at avg. $11.76$165K - Mar 2, 2026TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct7.2K shares at avg. $11.66$84K - Mar 1, 2026TRDA
Entrada Therapeutics, Inc.
Award(A)Direct55.8K shares- - Sep 2, 2025TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct1.7K shares at avg. $5.43$9K - Mar 3, 2025TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct5.1K shares at avg. $11.68$60K - Mar 1, 2025TRDA
Entrada Therapeutics, Inc.
Award(A)Direct60.8K shares- - Sep 26, 2024TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct847 shares at avg. $16.00$14K - Sep 9, 2024TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct1.9K shares at avg. $15.07$29K - Sep 6, 2024TRDA
Entrada Therapeutics, Inc.
Sale(S)Direct399 shares at avg. $15.19$6K - Sep 5, 2024TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct171 shares at avg. $15.13$3K - Sep 4, 2024TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct983 shares at avg. $15.42$15K - Sep 3, 2024TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct156 shares at avg. $16.93$3K - Sep 3, 2024TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct15 shares at avg. $17.70$265.53 - Sep 3, 2024TRDA
Entrada Therapeutics, Inc.
Tax Payment(F)Direct483 shares at avg. $15.76$8K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 2, 2026 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 2,528 | $7.14 | $18,060 | Direct |
| May 4, 2026 | TRDA Entrada Therapeutics, Inc. | Exercise(M) | 15,000 | $1.74 | $26,100 | Direct |
| May 4, 2026 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 15,000 | $15.33 | $229,953 | Direct |
| Mar 10, 2026 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 11,894 | $13.05 | $155,188 | Direct |
| Mar 9, 2026 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 3,116 | $13.02 | $40,583 | Direct |
| Mar 3, 2026 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 14,038 | $11.76 | $165,036 | Direct |
| Mar 2, 2026 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 7,223 | $11.66 | $84,205 | Direct |
| Mar 1, 2026 | TRDA Entrada Therapeutics, Inc. | Award(A) | 55,800 | - | $0 | Direct |
| Sep 2, 2025 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 1,746 | $5.43 | $9,481 | Direct |
| Mar 3, 2025 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 5,144 | $11.68 | $60,075 | Direct |
| Mar 1, 2025 | TRDA Entrada Therapeutics, Inc. | Award(A) | 60,800 | - | - | Direct |
| Sep 26, 2024 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 847 | $16.00 | $13,552 | Direct |
| Sep 9, 2024 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 1,904 | $15.07 | $28,690 | Direct |
| Sep 6, 2024 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 399 | $15.19 | $6,063 | Direct |
| Sep 5, 2024 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 171 | $15.13 | $2,587 | Direct |
| Sep 4, 2024 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 983 | $15.42 | $15,161 | Direct |
| Sep 3, 2024 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 156 | $16.93 | $2,640 | Direct |
| Sep 3, 2024 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 15 | $17.70 | $266 | Direct |
| Sep 3, 2024 | TRDA Entrada Therapeutics, Inc. | Tax Payment(F) | 483 | $15.76 | $7,613 | Direct |
1-19 of 19 transactions
About Dowden Nathan J
Dowden Nathan J (SEC CIK 0001873392) files insider reports with the SEC as President & COO of Entrada Therapeutics, Inc. (TRDA).
Signal8 holds 9 ownership filings by Dowden Nathan J, all Form 4s, filed between Sep 5, 2024 and Sep 3, 2026. Those filings report 19 transactions, from Sep 3, 2024 to Sep 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Dowden Nathan J's filings is in BOSTON, MA.
Recent filings by Dowden Nathan J
- Sep 2, 2026: Tax withholding of TRDA shares (Form 4, code F).
- May 4, 2026: Option exercise of TRDA shares (Form 4, code M).
- May 4, 2026: Open-market sale of TRDA shares (Form 4, code S).
- Mar 10, 2026: Open-market sale of TRDA shares (Form 4, code S).
- Mar 9, 2026: Open-market sale of TRDA shares (Form 4, code S).
Other insiders filing for Entrada Therapeutics, Inc. (TRDA)
- MPM BIOVENTURES 2018, L.P., 10% Owner
- MPM BioVentures 2014, L.P., 10% Owner
- Doshi Dipal, CEO
- Sethuraman Natarajan, President, Research & Develop.
- WENTWORTH KORY JAMES, Chief Financial Officer
- PARMAR KUSH, Director